In immunocompetent mice, we found that selective depletion of FRβ+ TAMs prior to the administration of mesothelin-specific CAR-T cells significantly improved engraftment and expansion of tumor-specific CAR-T cells and promoted a more robust endogenous T cell recruitment. The gene discussed is MSLN; the disease is neoplasm.